glp-1 obesity drug news october 21 2025 New Pill Foundayo (Orforglipron) Gets FDA Approval for GLP-1 Agonists: Using Semaglutide, Tirzepatide,

R&D expenses refer to the large amount of funds invested in the drug development process, which are usually allocated to the price of the drug

doi: 10.1016/j.phymed.2025.156901 158 PeiFDuanJTanLGuCMiaoJLiuSet al

55 In esophageal squamous cell carcinoma (ESCC), QSOX2 promotes disulfide bond formation in TSC2, enhancing its phosphorylation by Akt and activating the mTOR/4E-BP1/c-Myc axis, thereby upregulating CSC markers (e.g., CD44, Notch1) and promoting platinum resistance

Renal Lifecycle, A Randomized Controlled Clinical Trial to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe Chronic Kidney Disease (NCT05374291)